Miscellaneous Diagnostic Tests
The rapid detection tests consists of a self-contained collection cup and test device with auto-activated results seen in 5 minutes with no tipping of the cup.
The data informs labs and clinicians on the type of leukemia or lymphoma present by marking proteins found on the surface of cells with fluorescent dyes. These markers are further analyzed on a flow cytometer.
Although 49% of patients stay with their doctor for 5 years or more, the authors note that 1 quarter of patients are likely to switch physician if they find a doctor with a more positive attitude.
The approval for Tafinlar and Mekinist combination therapy was based on a Phase 2 international, multicenter, 3-cohort, non-randomized, non-comparative, open-label trial (Study BRF113928) in patients with locally confirmed stage IV NSCLC with BRAF V600E mutation.
Combining cholesterol uptake capacity with known cardiovascular disease risk factors also significantly improved the power of those factors to predict patients who would re-develop heart disease.
A paper-based test was created which requires a small sample of blood (10mcL). If the ST2 antigen is present in the sample, a blue dot appears on the strip; if the BNP antigen is present in the sample, then a green dot appears.
Certain lead tests manufactured by Magellan Diagnostics may have provided inaccurate results to patients, according to the Food and Drug Administration.
The ipsogen JAK2 RGQ PCR Kit test detected polycythemia vera with 94.6% sensitivity and 98.1% specificity, in the study the approval was based on.
While the GHR tests may provide genetic risk information, they cannot determine a person's overall risk for developing a disease, as other factors beyond genetics (ie, environment, lifestyle) may also influence risk.
Most studies supporting ketamine's benefit assessed efficacy during the first week following a single infusion; emerging studies indicate that repeated dosing may extend the efficacy for at least several weeks.
Measuring blood neurofilament light chain (NfL) levels may help distinguish Parkinson's disease (PD) from atypical parkinsonian disorders (APD), according to a study published onlinein Neurology.
Quest Diagnostics announced the availability of a new test to aid physicians in evaluating a patient's response to drug treatments for hepatitis B virus (HBV) infection. This first-of-its-kind test can help physicians prescribe more effective treatments for patients with HBV.
For patients admitted to the intensive care unit (ICU), procalcitonin (PCT) testing on the first day of admission is associated with significantly lower length stay in the hospital and ICU, according to a study published in the January issue of CHEST.
A simple blood test may one day diagnose concussions with more than 90% certainty, according to a study published online October 28 in Metabolomics.
A five-item questionnaire plus peak expiratory flow (PEF) can identify undiagnosed chronic obstructive pulmonary disease (COPD), according to a study published online in the American Journal of Respiratory and Critical Care Medicine.
BD announced that the Food and Drug Administration (FDA) has granted marketing clearance for BD MAX Vaginal Panel to detect the most common causes for vaginitis.
AstraZeneca announced that the Food and Drug Administration (FDA) has approved cobas EGFR Mutation Test v2, a companion diagnostic for Tagrisso (osimertinib).
Compared with current recommendations from professional societies, expanded carrier screening may increase the detection of carrier status for potentially serious genetic conditions, according to a study published in the Journal of the American Medical Association.
The U.S. Preventive Services Task Force (USPSTF) has concluded that the evidence is currently insufficient to weigh the balance of benefits and harms of screening for lipid disorders in children and adolescents (aged 20 years or younger). These findings form the basis of a final recommendation statement published in the August 9 issue of the Journal of the American Medical Association.
Limiting first trimester screening (FTS) by cell-free fetal (cff) DNA to only patients in certain risk categories may be a feasible cost-containing strategy, according to a study published online in the Journal of Evaluation in Clinical Practice.
The Food and Drug Administration (FDA) has cleared Xpert Carba-R Assay, the first test to detect specific genetic markers associated with bacteria that are resistant to carbapenem antibiotics.